166 related articles for article (PubMed ID: 23151808)
1. Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma.
Gangadhar TC; Clark JI; Karrison T; Gajewski TF
Invest New Drugs; 2013 Jun; 31(3):769-73. PubMed ID: 23151808
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.
Lara PN; Longmate J; Evans CP; Quinn DI; Twardowski P; Chatta G; Posadas E; Stadler W; Gandara DR
Anticancer Drugs; 2009 Mar; 20(3):179-84. PubMed ID: 19396016
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.
Reddy SM; Kopetz S; Morris J; Parikh N; Qiao W; Overman MJ; Fogelman D; Shureiqi I; Jacobs C; Malik Z; Jimenez CA; Wolff RA; Abbruzzese JL; Gallick G; Eng C
Invest New Drugs; 2015 Aug; 33(4):977-84. PubMed ID: 26062928
[TBL] [Abstract][Full Text] [Related]
4. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.
Baselga J; Cervantes A; Martinelli E; Chirivella I; Hoekman K; Hurwitz HI; Jodrell DI; Hamberg P; Casado E; Elvin P; Swaisland A; Iacona R; Tabernero J
Clin Cancer Res; 2010 Oct; 16(19):4876-83. PubMed ID: 20805299
[TBL] [Abstract][Full Text] [Related]
5. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.
Yang JC; Bai L; Yap S; Gao AC; Kung HJ; Evans CP
Mol Cancer Ther; 2010 Jun; 9(6):1629-37. PubMed ID: 20484016
[TBL] [Abstract][Full Text] [Related]
6. Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study.
Hannon RA; Finkelman RD; Clack G; Iacona RB; Rimmer M; Gossiel F; Baselga J; Eastell R
Bone; 2012 Apr; 50(4):885-92. PubMed ID: 22245630
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium.
Mackay HJ; Au HJ; McWhirter E; Alcindor T; Jarvi A; MacAlpine K; Wang L; Wright JJ; Oza AM
Invest New Drugs; 2012 Jun; 30(3):1158-63. PubMed ID: 21400081
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium.
Laurie SA; Goss GD; Shepherd FA; Reaume MN; Nicholas G; Philip L; Wang L; Schwock J; Hirsh V; Oza A; Tsao MS; Wright JJ; Leighl NB
Clin Lung Cancer; 2014 Jan; 15(1):52-7. PubMed ID: 24169259
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer.
Gucalp A; Sparano JA; Caravelli J; Santamauro J; Patil S; Abbruzzi A; Pellegrino C; Bromberg J; Dang C; Theodoulou M; Massague J; Norton L; Hudis C; Traina TA
Clin Breast Cancer; 2011 Oct; 11(5):306-11. PubMed ID: 21729667
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621.
Molina JR; Foster NR; Reungwetwattana T; Nelson GD; Grainger AV; Steen PD; Stella PJ; Marks R; Wright J; Adjei AA
Lung Cancer; 2014 Aug; 85(2):245-50. PubMed ID: 24957683
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer.
Schweppe RE; Kerege AA; French JD; Sharma V; Grzywa RL; Haugen BR
J Clin Endocrinol Metab; 2009 Jun; 94(6):2199-203. PubMed ID: 19293266
[TBL] [Abstract][Full Text] [Related]
12. First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours.
Fujisaka Y; Onozawa Y; Kurata T; Yasui H; Goto I; Yamazaki K; Machida N; Watanabe J; Shimada H; Shi X; Boku N
Invest New Drugs; 2013 Feb; 31(1):108-14. PubMed ID: 22415795
[TBL] [Abstract][Full Text] [Related]
13. Dual Drug Repurposing: The Example of Saracatinib.
Ramos R; Vale N
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674150
[TBL] [Abstract][Full Text] [Related]
14. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530.
Green TP; Fennell M; Whittaker R; Curwen J; Jacobs V; Allen J; Logie A; Hargreaves J; Hickinson DM; Wilkinson RW; Elvin P; Boyer B; Carragher N; Plé PA; Bermingham A; Holdgate GA; Ward WH; Hennequin LF; Davies BR; Costello GF
Mol Oncol; 2009 Jun; 3(3):248-61. PubMed ID: 19393585
[TBL] [Abstract][Full Text] [Related]
15. Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion.
Ferguson J; Arozarena I; Ehrhardt M; Wellbrock C
Oncogene; 2013 Jan; 32(1):86-96. PubMed ID: 22310287
[TBL] [Abstract][Full Text] [Related]
16. Effects of Src-kinase inhibition in cancer-induced bone pain.
De Felice M; Lambert D; Holen I; Escott KJ; Andrew D
Mol Pain; 2016; 12():. PubMed ID: 27094550
[TBL] [Abstract][Full Text] [Related]
17. Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib.
Lang L; Shay C; Xiong Y; Thakkar P; Chemmalakuzhy R; Wang X; Teng Y
J Hematol Oncol; 2018 Jun; 11(1):85. PubMed ID: 29925404
[TBL] [Abstract][Full Text] [Related]
18. The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines.
Gwanmesia PM; Romanski A; Schwarz K; Bacic B; Ruthardt M; Ottmann OG
BMC Cancer; 2009 Feb; 9():53. PubMed ID: 19216789
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies.
Gubens MA; Burns M; Perkins SM; Pedro-Salcedo MS; Althouse SK; Loehrer PJ; Wakelee HA
Lung Cancer; 2015 Jul; 89(1):57-60. PubMed ID: 26009269
[TBL] [Abstract][Full Text] [Related]
20. Src-signaling interference impairs the dissemination of blood-borne tumor cells.
Siemann DW; Dong M; Pampo C; Shi W
Cell Tissue Res; 2012 Aug; 349(2):541-50. PubMed ID: 22526632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
